Bank of New York Mellon’s Dr. Reddy's Laboratories RDY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $542K | Buy |
37,381
+48
| +0.1% | +$648 | ﹤0.01% | 3709 |
|
|
2026
Q1 | $517K | Sell |
37,333
-31,821
| -46% | -$443K | ﹤0.01% | 3582 |
|
|
2025
Q4 | $971K | Buy |
69,154
+3,813
| +6% | +$53.5K | ﹤0.01% | 3253 |
|
|
2025
Q3 | $913K | Buy |
65,341
+911
| +1% | +$13.1K | ﹤0.01% | 3259 |
|
|
2025
Q2 | $968K | Sell |
64,430
-15,863
| -20% | -$227K | ﹤0.01% | 3139 |
|
|
2025
Q1 | $1.06M | Sell |
80,293
-1,713
| -2% | -$23.6K | ﹤0.01% | 3035 |
|
|
2024
Q4 | $1.29M | Sell |
82,006
-28,374
| -26% | -$426K | ﹤0.01% | 2992 |
|
|
2024
Q3 | $1.75M | Sell |
110,380
-23,460
| -18% | -$378K | ﹤0.01% | 2819 |
|
|
2024
Q2 | $2.04M | Buy |
133,840
+2,445
| +2% | +$35K | ﹤0.01% | 2779 |
|
|
2024
Q1 | $1.93M | Sell |
131,395
-57,450
| -30% | -$839K | ﹤0.01% | 2778 |
|
|
2023
Q4 | $2.63M | Sell |
188,845
-1,675
| -0.9% | -$22.4K | ﹤0.01% | 2691 |
|
|
2023
Q3 | $2.55M | Sell |
190,520
-147,810
| -44% | -$2M | ﹤0.01% | 2673 |
|
|
2023
Q2 | $4.27M | Sell |
338,330
-49,300
| -13% | -$576K | ﹤0.01% | 2412 |
|
|
2023
Q1 | $4.41M | Sell |
387,630
-5,145
| -1% | -$55.5K | ﹤0.01% | 2370 |
|
|
2022
Q4 | $4.07M | Sell |
392,775
-640
| -0.2% | -$6.91K | ﹤0.01% | 2454 |
|
|
2022
Q3 | $4.12M | Buy |
393,415
+240
| +0.1% | +$2.56K | ﹤0.01% | 2391 |
|
|
2022
Q2 | $4.36M | Buy |
393,175
+1,930
| +0.5% | +$21K | ﹤0.01% | 2390 |
|
|
2022
Q1 | $4.36M | Buy |
391,245
+355,085
| +982% | +$4.03M | ﹤0.01% | 2499 |
|
|
2021
Q4 | $473K | Sell |
36,160
-770
| -2% | -$9.71K | ﹤0.01% | 3843 |
|
|
2021
Q3 | $482K | Buy |
36,930
+5,935
| +19% | +$79.1K | ﹤0.01% | 3830 |
|
|
2021
Q2 | $456K | Sell |
30,995
-320
| -1% | -$4.47K | ﹤0.01% | 3809 |
|
|
2021
Q1 | $385K | Sell |
31,315
-105,785
| -77% | -$1.36M | ﹤0.01% | 3822 |
|
|
2020
Q4 | $1.96M | Sell |
137,100
-251,605
| -65% | -$3.39M | ﹤0.01% | 2861 |
|
|
2020
Q3 | $5.41M | Buy |
388,705
+4,330
| +1% | +$51.6K | ﹤0.01% | 2171 |
|
|
2020
Q2 | $4.08M | Buy |
384,375
+43,130
| +13% | +$439K | ﹤0.01% | 2311 |
|
|
2020
Q1 | $2.75M | Buy |
341,245
+290,000
| +566% | +$2.42M | ﹤0.01% | 2379 |
|
|
2019
Q4 | $416K | Sell |
51,245
-45,005
| -47% | -$355K | ﹤0.01% | 3682 |
|
|
2019
Q3 | $729K | Sell |
96,250
-40,755
| -30% | -$303K | ﹤0.01% | 3343 |
|
|
2019
Q2 | $1.03M | Buy |
137,005
+22,935
| +20% | +$180K | ﹤0.01% | 3191 |
|
|
2019
Q1 | $924K | Buy |
114,070
+26,485
| +30% | +$201K | ﹤0.01% | 3240 |
|
|
2018
Q4 | $661K | Buy |
87,585
+4,720
| +6% | +$33.2K | ﹤0.01% | 3333 |
|
|
2018
Q3 | $573K | Sell |
82,865
-2,500
| -3% | -$16.7K | ﹤0.01% | 3578 |
|
|
2018
Q2 | $550K | Buy |
85,365
+7,110
| +9% | +$44.9K | ﹤0.01% | 3596 |
|
|
2018
Q1 | $512K | Sell |
78,255
-90,035
| -53% | -$631K | ﹤0.01% | 3580 |
|
|
2017
Q4 | $1.26M | Sell |
168,290
-690
| -0.4% | -$4.97K | ﹤0.01% | 3112 |
|
|
2017
Q3 | $1.21M | Buy |
168,980
+27,705
| +20% | +$199K | ﹤0.01% | 3133 |
|
|
2017
Q2 | $1.19M | Buy |
141,275
+104,390
| +283% | +$849K | ﹤0.01% | 3151 |
|
|
2017
Q1 | $297K | Buy |
+36,885
| New | +$319K | ﹤0.01% | 3753 |
|
|
2016
Q3 | – | Sell |
-31,605
| Closed | -$324K | – | 4307 |
|
|
2016
Q2 | $324K | Sell |
31,605
-25
| -0.1% | -$229 | ﹤0.01% | 3717 |
|
|
2016
Q1 | $286K | Sell |
31,630
-55,520
| -64% | -$496K | ﹤0.01% | 3661 |
|
|
2015
Q4 | $807K | Sell |
87,150
-137,070
| -61% | -$1.5M | ﹤0.01% | 3302 |
|
|
2015
Q3 | $2.87M | Buy |
224,220
+33,195
| +17% | +$412K | ﹤0.01% | 2526 |
|
|
2015
Q2 | $2.11M | Sell |
191,025
-43,605
| -19% | -$481K | ﹤0.01% | 2879 |
|
|
2015
Q1 | $2.68M | Sell |
234,630
-47,515
| -17% | -$504K | ﹤0.01% | 2663 |
|
|
2014
Q4 | $2.85M | Buy |
+282,145
| New | +$2.97M | ﹤0.01% | 2626 |
|
|
2013
Q3 | – | Sell |
-175,755
| Closed | -$1.33M | – | 4196 |
|
|
2013
Q2 | $1.33M | Buy |
+175,755
| New | +$1.28M | ﹤0.01% | 3023 |
|
Other funds holding RDY
AIM
N
Bank of New York Mellon's RDY Position: Q2 2026 in Review
Bank of New York Mellon increased its Dr. Reddy's Laboratories (RDY) stake by 0.13% in Q2 2026, buying an estimated $648 and bringing the position to 37,381 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #3709.
Bank of New York Mellon first reported a position in RDY in Q2 2013 and has held it in 46 quarters since. The position peaked at $5.41M in Q3 2020. 158 funds tracked by Wall St. Rank hold RDY as of Q2 2026.
- Bank of New York Mellon held 37,381 shares of Dr. Reddy's Laboratories worth $542K as of Q2 2026.
- Bank of New York Mellon bought 48 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $648.
- Dr. Reddy's Laboratories made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3709 holding.
- Bank of New York Mellon first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 46 quarters since.
- Bank of New York Mellon's Dr. Reddy's Laboratories position peaked at $5.41M in Q3 2020.
- 158 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.